Compare NUTX & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUTX | ABUS |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.5M | 848.1M |
| IPO Year | N/A | N/A |
| Metric | NUTX | ABUS |
|---|---|---|
| Price | $160.95 | $4.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $252.50 | $5.00 |
| AVG Volume (30 Days) | 199.2K | ★ 1.1M |
| Earning Date | 11-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 17.98 | N/A |
| Revenue | ★ $981,195,633.00 | $14,606,000.00 |
| Revenue This Year | $104.36 | $125.30 |
| Revenue Next Year | $4.10 | N/A |
| P/E Ratio | $8.95 | ★ N/A |
| Revenue Growth | ★ 236.03 | 116.64 |
| 52 Week Low | $28.12 | $2.71 |
| 52 Week High | $184.28 | $5.10 |
| Indicator | NUTX | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 68.36 | 50.01 |
| Support Level | $107.09 | $4.09 |
| Resistance Level | $145.02 | $4.47 |
| Average True Range (ATR) | 14.61 | 0.20 |
| MACD | 3.86 | -0.00 |
| Stochastic Oscillator | 98.91 | 54.18 |
Nutex Health Inc is healthcare services and operations company with 20 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospital division implements and operates healthcare models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management division owns and operates provider networks such as independent physician associations (IPAs) and offers a cloud-based proprietary technology platform to IPAs that aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.